Pharmacological and clinical profile of mitiglinide calcium hydrate (Glufast®), a new insulinotropic agent with rapid onset

Folia Pharmacologica Japonica

Volumn 124, Issue 4, 2004, Pages 245-255

  Ojima, Kazuma ^a   Kiyono, Yuji ^a   Kojima, Masami ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Insulin; Mitiglinide; Postprandial hyperglycemia; Sulfonylurea receptor (SUR); Type 2 diabetes

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLIBENCLAMIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; MITIGLINIDE; NATEGLINIDE; PLACEBO; POTASSIUM CHANNEL;

CELL TYPE; CLINICAL TRIAL; DIET RESTRICTION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; INSULIN RELEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DOGS; HUMANS; HYPOGLYCEMIC AGENTS; INDOLES; INSULIN; RATS;

EID: 7044224714     PISSN: 00155691     EISSN: None     Source Type: Journal    
DOI: 10.1254/fpj.124.245     Document Type: Review

References (41)

1. Polonsky KS, Given BD, Van Cauter E. Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest. 1988;81:442-448.
2. Schuit FC, Huypens P, Heimberg H, Pipeleers DG. Glucose sensing in pancreatic β-cells. Diabetes. 2001;50:1-11.
3. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop Type 2 diabetes? Diabetes. 2002;51 Suppl 1:S117-S121.
4. LeRoith D. β-cell dysfunction and insulin resistance in type 2 diabetes: Role of metabolic and genetic abnormalities. Am J Med. 2002;113 Suppl 6A: 3S-11S.
5. Del Prato S. Loss of early insulin secretion leads to postprandial hyperglycemia. Diabetologia, 2003;46 Suppl 1:M2-M8.
6. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev. 2002;18 Suppl 3:S9-S13.
7. Zimmet P, Alberti KGMM, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414:782-787.
8. Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Are oxidative stress-activated signaling pathways mediators of insulin resistance and β-cell dysfunction? Diabetes. 2003;52:1-8
9. World Health organization: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus. In "Report of a WHO Consultation", World Health Organization, Geneva, 1999, p. 1-59.
10. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia. 2003;46 Suppl 1:M9-M16.
11. The DECODE study group: Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. European Diabetes Epidemiology Group. Diabetes epidemiology collaborative analysis of diagnostic criteria in Europe. Lancet. 1999;354:617-621.
12. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. Diabetes Care. 1999;22:920-924.
13. Hanefeld M, Fischer S, Julius U, Schulze J, Schwanebeck U, Schmechel H, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia. 1996;39:1577-1583.
14. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17: 467-473.
15. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulfonylureas. Diabetes. 1998;47: 1412-1418.
16. Dorschner H, Brekardin E, Uhde I, Schwanstecher C, Schwanstecher M. Stoichiometry of sulfonylurea-induced ATP-sensitive potassium channel closure. Mol Pharmacol. 1999;56:1060-1066.
17. Cleveland JC, Meldrum DR, Cain BS, Banerjee A, Harken AH. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Circulation. 1997;96:29-32.
18. Legtenberg RJ, Houston RJF, Oeseburg B, Smits P. Effects of sulfonylurea derivatives on ischemia-induced loss of function in the isolated rat heart. Eur J Pharmacol. 2001;419:85-92.
19. Taverna MJ, Pacher N, Bruzzo F, Slama G, Selam JL. Beta-cell function evaluated by HOMA as a predictor of secondary failure in Type 2 diabetes. Diabet Med. 2001;18:584-588.
20. Proks P, Reimann F, Green N, Gribble F, Achcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes. 2002;51 Suppl 3:S368-S376.
21. + channels. Neuron. 1996;16:1011-1017.
22. Ashcroft FM, Rorsman P. Electrophysiology of the pancreatic β-cell. Prog Biophys Mol Biol. 1989;54: 87-143.
23. Gerber SH, Sudhof TC. Molecular determinants of regulated exocytosis. Diabetes. 2002;51 Suppl 1:S3-S11.
24. Ikenoue T, Akiyoshi M, Fujitani S, Okazaki K, Kondo N, Maki T. Hypoglycaemic and insulinotropic effects of a novel oral antidiabetic agents, (-) -N- (trans-4-isopropylcyclo-hexane-carbonyl) -D-phenylalanine (A-4166). Br J Pharmacol. 1997;120: 137-145.
25. ATP channels. J Pharmacol Exp Ther. 2003;304:1025-1032.
26. Standl E, Füchtenbusch M. The role of oral antidiabetic agents: why and when to use an early-phase insulin secretion agent in Type 2 diabetes mellitus. Diabetologia. 2003;46 Suppl1:M30-M36.
27. Ohnota H, Koizumi T, Tsutsumi N, Kobayashi M, Inoue S, Sato F. Novel rapid- and short-acting hypoglycemic agent, a calcium (2s)-2-benzyl-3-(cis- hexahydro-2-isoindolinyl-carbonyl) propionate (KAD-1229) that acts on the sulfonylurea receptor: comparison of effects between KAD-1229 and gliclazide. J Pharmacol Exp Ther. 1994;269:489-495.
28. + channel in insulin-secreting pancreatic β-cell. J Mol Endocrinol. 1999; 22:113-123.
29. Ashfield R, Gribble FM, Ashcroft SJH, Ashcroft FM. Identification of the high-affinity tolbutamide site on the SUR1 subunit of the KATP channel. Diabetes. 1999;48:1341-1347.
30. Ichikawa K, Yamato T, Tsuji A, Ojima K, Kusama H, Kojima M. Study of the insulinotropic effect of the novel antihypoglycemic agent KAD-1229 using HIT T15 cells, a hamster's insulinoma cell line. Arzneimittelforschung. 2002;52:605-609.
31. Reimann F, Proks P, Ashcroft FM. Effects of mitiglinide (S 21403) on Kir6.2/SUR1, Kir6.2/SUR 2A and Kir6.2/SUR2B types of ATP-sensitive potassium channel. Br J Pharmacol. 2001;132:1542-1548.
32. + channels in the absence of the sulfonylurea receptor. Nature. 1997;387:179-183.
33. Ichikawa K, Maruyama K, Murakami M, Tsuji A, Yamato T, Kusama H, et al. Absence of exacerbation of myocardial stunning in anesthetized dogs treated with KAD-1229, novel hypoglycemic agent. Eur J Pharmacol. 2001;431:331-338.
34. Gerich JE. Is reduced first-phase insulin release the earliest detectable abnormality in individuals destined to develop type 2 diabetes? Diabetes. 2002; 51 Suppl 1:S117-S121.
35. Gregorio F, Ambrosi F, Boemi M, Carle F, Filipponi P. Effects of S21403 on hormone secretion from isolated rat pancreas at different glucose concentrations. Eur J Pharmacol. 2002;456:141-147.